249 related articles for article (PubMed ID: 36410041)
1. Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Peng W; Zhang Y; Li X; Lin Y
J Cardiovasc Pharmacol; 2023 Feb; 81(2):134-140. PubMed ID: 36410041
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China.
Zhang Y; Zhang Y; Shi X; Lin B; Han J; Wang Y; Yan J; Peng W; Li W; Zheng Z; Lin Y
Thromb Haemost; 2022 May; 122(5):842-852. PubMed ID: 34428831
[TBL] [Abstract][Full Text] [Related]
4. Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Wang HY; Li Y; Xu XM; Li J; Han YL
Chin Med J (Engl); 2018 Sep; 131(17):2017-2024. PubMed ID: 30127210
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A GRACE Risk Score Stratification-Based Analysis in a Large-Scale, Real-World Study From China.
Qiu M; Na K; Qi Z; Zhou H; Li P; Xu K; Wang B; Liu H; Li J; Li Y; Han Y
Mayo Clin Proc; 2023 Jul; 98(7):1021-1032. PubMed ID: 37419570
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
[TBL] [Abstract][Full Text] [Related]
7. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
[TBL] [Abstract][Full Text] [Related]
8. In-hospital outcomes of ticagrelor versus clopidogrel in patients 75 years or older with acute coronary syndrome: findings from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome Project.
Yang N; Liu J; Liu J; Hao Y; Smith JSC; Huo Y; Fonarow GC; Ge J; Morgan L; Ma C; Han Y; Zhao D;
Age Ageing; 2022 Nov; 51(11):. PubMed ID: 36413586
[TBL] [Abstract][Full Text] [Related]
9. A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Li Y; Lei M; Yang Y; An L; Zhou H; Wang J; Zhao Z; Wang X; Nie S; Wang X; Hau WK; Xue Z
Medicine (Baltimore); 2023 Jul; 102(27):e34153. PubMed ID: 37417626
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Xu S; Liang Y; Chen Y; Gao H; Tan Z; Wang Q; Liu Y; Zhu B; Tao F; Wang Q; Zhao S; Yang L; Zhang Y; Wang Z; Han P; Chen Y; Zhang A; Li C; Lian K
Drugs Aging; 2022 Sep; 39(9):695-703. PubMed ID: 35995912
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan.
Li YS; Wang SH; Hwang SJ; Yang YH; Hsieh KP
Br J Clin Pharmacol; 2022 Jan; 88(1):145-154. PubMed ID: 34080719
[TBL] [Abstract][Full Text] [Related]
12. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
13. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis.
Zhao X; Ai G; Qiu M; Wang X; Zhang L; Yang X; Liu Y; Xu P; Zhang J; Gu C; Zhou M; Hao Y; Zhao D; Han Y;
Int J Cardiol; 2020 Jul; 310():1-8. PubMed ID: 32307186
[TBL] [Abstract][Full Text] [Related]
15. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.
Li Y; Li J; Qiu M; Ma S; Na K; Li X; Qi Z; Chen S; Li Y; Han Y
Catheter Cardiovasc Interv; 2022 May; 99 Suppl 1():1395-1402. PubMed ID: 35032148
[TBL] [Abstract][Full Text] [Related]
17. In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: Findings from the CCC-ACS project.
Wang Y; Yang N; Suo M; Liu X; Wang Z; Zhang X; Liu J; Zhao D; Wu X;
Thromb Res; 2022 Aug; 216():43-51. PubMed ID: 35714445
[TBL] [Abstract][Full Text] [Related]
18. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.
Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW
Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R
Platelets; 2020; 31(3):337-343. PubMed ID: 31043110
[TBL] [Abstract][Full Text] [Related]
20. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
